公开(公告)号：US20170029520A1

公开(公告)日：2017-02-02

申请号：US15195883

申请日：2016-06-28

Applicant: Genentech, Inc.

Inventor： Paul BRUNETTA ,  Dominique BORIE

IPC: C07K16/28

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515

Abstract: The present disclosure provides, inter alia, methods for treating an individual in need of an organ transplantation, such as a renal transplantation, by administering to the individual an effective amount of a type II anti-CD20 antibody before, concurrently with, and/or after the transplantation. In some embodiments, the methods may reduce alloantibodies, Panel Reactive Antibodies (PRA), and/or risk of graft rejection. In some embodiments, the methods further comprise administering to the individual a dose of intravenous immunoglobulin (IVIG) before the transplantation.

Abstract translation: 本公开尤其提供了用于治疗需要器官移植（例如肾移植）的个体的方法，其通过在个体之前，同时和/或/或其之间给予个体有效量的II型抗CD20抗体 移植后。 在一些实施方案中，所述方法可以减少同种异体抗体，面板反应性抗体（PRA）和/或移植排斥的风险。 在一些实施方案中，所述方法还包括在移植前向个体施用一剂静脉内免疫球蛋白（IVIG）。

公开(公告)号：US20240033351A1

公开(公告)日：2024-02-01

申请号：US18045313

申请日：2022-10-10

Applicant: Genentech, Inc.

Inventor： Paul BRUNETTA

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/138 ,  A61K31/167 ,  A61K31/5377 ,  A61K31/573 ,  A61K45/06

CPC classification number: A61K39/3955 ,  C07K16/2887 ,  A61K31/138 ,  A61K31/167 ,  A61K31/5377 ,  A61K31/573 ,  A61K45/06 ,  C07K2317/71 ,  C07K2317/24 ,  C07K2317/77 ,  C07K2317/41 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/524 ,  C07K2317/70 ,  A61K2039/507

Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

公开(公告)号：US20160346387A1

公开(公告)日：2016-12-01

申请号：US15151449

申请日：2016-05-10

Applicant: Genentech, Inc.

Inventor： Paul BRUNETTA

IPC: A61K39/395 ,  A61K31/167 ,  A61K31/573 ,  A61K31/138 ,  A61K45/06 ,  A61K31/5377

CPC classification number: A61K39/3955 ,  A61K31/138 ,  A61K31/167 ,  A61K31/5377 ,  A61K31/573 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/77

Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

Abstract translation: 本发明提供了治疗或延缓患有狼疮的个体的狼疮肾炎进展的方法。 在一些实施方案中，所述方法包括向个体施用有效量的II型抗-CD20抗体。 本发明还提供了治疗或延缓个体中类风湿性关节炎（RA）或系统性红斑狼疮（SLE）进展的方法。 在一些实施方案中，所述方法包括施用有效量的抗CD20抗体。